I can tell you confidently that the leave entitlements are from staff turn over due to poor management and cultur - long serving employees who arep pulling the pin. I can also tell you there's more to come, from key personnel who were capable of driving growth, leaving only the chumps behind.
They will keep buying businesses, hence the CR, but make no mistake, their ability to organically grow the business is practically non existent and the tech and solutions they are investing in will be obsolete before they get a remotely working model.
I am close with a number of people across a number of those organisations and have first hand knowledge so this is not downramping, simply my view of the world and what I consider a warning (the same I would love to see if I was invested in something).
As with my stake in QFE, you can choose to ignore the naysayers and hold/buy in/buy more and that's completely fine, this is just another piece of info you can choose to utilise in your research
Best of luck gents.
- Forums
- ASX - By Stock
- 5GN
- Ann: Appendix 4C - quarterly
Ann: Appendix 4C - quarterly, page-10
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 5GN (ASX) to my watchlist
|
|||||
Last
15.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $46.96M |
Open | High | Low | Value | Volume |
15.0¢ | 15.3¢ | 15.0¢ | $86.66K | 577.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 4670865 | 15.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
15.5¢ | 1548308 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 4670865 | 0.150 |
5 | 1830344 | 0.145 |
4 | 164180 | 0.140 |
4 | 32228 | 0.135 |
2 | 15398 | 0.130 |
Price($) | Vol. | No. |
---|---|---|
0.155 | 1463308 | 23 |
0.160 | 698265 | 14 |
0.165 | 245845 | 6 |
0.170 | 504284 | 5 |
0.175 | 52258 | 3 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
5GN (ASX) Chart |